Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported EBITDA Margin over the past 12 years, most recently at 91114.39% for Q4 2025.

  • Quarterly results put EBITDA Margin at 91114.39% for Q4 2025, up 2092311.0% from a year ago — trailing twelve months through Dec 2025 was 482.92% (up 8901940.0% YoY), and the annual figure for FY2025 was 482.92%, up 8901940.0%.
  • EBITDA Margin for Q4 2025 was 91114.39% at Viridian Therapeutics, Inc.\DE, down from 48.61% in the prior quarter.
  • Over the last five years, EBITDA Margin for VRDN hit a ceiling of 48.61% in Q3 2025 and a floor of 134548.0% in Q2 2025.
  • Median EBITDA Margin over the past 5 years was 67220.83% (2024), compared with a mean of 55060.07%.
  • Biggest five-year swings in EBITDA Margin: tumbled -6489961bps in 2023 and later skyrocketed 8740953bps in 2025.
  • Viridian Therapeutics, Inc.\DE's EBITDA Margin stood at 13598.13% in 2021, then crashed by -217bps to 43080.95% in 2022, then crashed by -114bps to 92302.78% in 2023, then decreased by -21bps to 112037.5% in 2024, then rose by 19bps to 91114.39% in 2025.
  • The last three reported values for EBITDA Margin were 91114.39% (Q4 2025), 48.61% (Q3 2025), and 134548.0% (Q2 2025) per Business Quant data.